

we will honor to the extent allowable by law. There also may be circumstances in which we would withhold a respondent's identity from public disclosure, as allowed by law. If you wish us to withhold your name and/or address, you must state this prominently at the beginning of your comment. We will make all submissions from organizations or businesses, and from individuals identifying themselves as representatives or officials of organizations or businesses, available for public disclosure in their entirety.

**FOR FURTHER INFORMATION CONTACT:**  
Dave Kaumheimer, Environmental Programs Manager, Bureau of Reclamation, telephone: (509) 575-5848 x232; fax: (509) 454-5650.

The meeting facilities are physically accessible to people with disabilities. Please direct requests for sign language interpretation for the hearing impaired, or other auxiliary aids, to Dave Kaumheimer at (509) 575-5848 x232 via toll free TTY relay (800) 833-6388 by April 11, 2000.

**SUPPLEMENTARY INFORMATION:**

**Background**

Keechelus Dam was constructed at the lower end of a natural lake on the Yakima River about 10 miles northwest of Easton, Washington, in Kittitas County. This earthfill structure was constructed between 1913 and 1917 and is approximately 6,550 feet long with a maximum height of 128 feet. It creates a reservoir with an active storage capacity of 158,000 acre-feet.

In June 1998, during the excavation of a trench for a telephone line conduit, a void was found in the crest of Keechelus Dam. This discovery led to further geotechnical investigations, including ground penetrating radar and geologic exploration activities, to determine the condition of the overall dam.

Subsequent investigations identified more than 40 potential void sites and significant evidence of dam embankment deterioration from seepage which could lead to embankment failure. As an interim safety measure, Keechelus Reservoir has been operated at a restricted full pool elevation 7 feet below the normal full pool elevation since November 1998, with increased technical monitoring and surveillance at the dam.

The scope of this document will focus on correcting the dam safety deficiencies at Keechelus Dam to protect property and the lives of people living downstream from the dam, and evaluating the potential impacts associated with the proposed alternatives. Correcting the SOD

deficiencies in no way restricts potential future modifications to the structure.

**Public Involvement**

Reclamation plans to conduct public scoping meetings to solicit input on the alternatives developed to correct safety deficiencies at Keechelus Dam and to identify potential issues and impacts associated with those alternatives. Reclamation will summarize comments received during the scoping meetings and from letters of comment received during the scoping period, identified under **DATES**, into a scoping summary document which will be made available to the public.

Dated: March 24, 2000.

**Max B. Gallegos,**

*Acting Regional Director, Pacific Northwest Region.*

[FR Doc. 00-7812 Filed 3-29-00; 8:45 am]

**BILLING CODE 4310-94-M**

Issued: March 27, 2000.

By order of the Commission.

**Donna R. Koehnke,**

*Secretary.*

[FR Doc. 00-7833 Filed 3-29-00; 8:45 am]

**BILLING CODE 7020-02-P**

**INTERNATIONAL TRADE COMMISSION**

**Sunshine Act Meeting**

**AGENCY HOLDING THE MEETING:** United States International Trade Commission.

**TIME AND DATE:** April 14, 2000 at 10 a.m.

**PLACE:** Room 101, 500 E Street S.W., Washington, DC 20436, Telephone: (202) 205-2000.

**STATUS:** Open to the public.

**MATTERS TO BE CONSIDERED:**

1. Agenda for future meeting: None.
2. Minutes.
3. Ratification List.
4. Inv. Nos. 731-TA-868-871

(Preliminary) (Steel Wire Rope from China, India, Malaysia, and Thailand)—briefing and vote. (The Commission will transmit its determination to the Secretary of Commerce on April 17, 2000.)

5. Outstanding action jackets: None.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission.

Issued: March 24, 2000.

**Donna R. Koehnke,**

*Secretary.*

[FR Doc. 00-7995 Filed 3-28-00; 2:05 pm]

**BILLING CODE 7020-02-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlling Substances; Notice of Registration**

By Notice dated December 16, 1999, and published in the **Federal Register** on December 28, 1999, (64 FR 248), Celgene Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of methylphenidate (1724), a basic class of controlled substance listed in Schedule II.

The firm plans to manufacturer methylphenidate for product research and development.

No comments or objections have been received. DEA has considered the

**Background**

The Commission instituted this review on August 2, 1999 (64 FR 41951, August 2, 1999) and determined on November 4, 1999 that it would conduct an expedited review (64 FR 62688, November 17, 1999). The Commission transmitted its determination in this review to the Secretary of Commerce on March 27, 2000. The views of the Commission are contained in USITC Publication 3285 (March 2000), entitled Electroluminescent Flat Panel Displays from Japan: Investigation No. 731-TA-469 (Review).

<sup>1</sup> The record is defined in sec. 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR 207.2(f)).

<sup>2</sup> Commissioners Askey and Okun dissenting. Vice Chairman Miller did not participate in this five-year review.

factors in Title 21, United States Code, Section 823(a) and determined that the registration of Celgene Corporation to manufacturer methylphenidate is consistent with the public interest at this time, DEA has investigated the Celgene Corporation on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR § 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Dated: March 23, 2000.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 00-7872 Filed 3-29-00; 8:45 am]

BILLING CODE 4410 09 M

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with § 1301.34 of title 21, Code of Federal Regulations (CFR), notice is hereby given that on October 19, 1999, Chirex Technology Center, Inc., DBA Chirex Cauldron, 383 Phoenixville Pike, Malvern, Pennsylvania 19355, made application by letter to the Drug Enforcement Administration to be registered as an importer of amphetamine (1100), a basic class of controlled substance listed in Schedule II.

The firm plans to import the amphetamine for the manufacture of a finished product.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled substance may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.43 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than May 1, 2000.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745-46 (September 23, 1975), all applicants for registration to import basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(a), (b), (c), (d), (e), and (f) are satisfied.

Dated: March 23, 2000.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 00-7870 Filed 3-29-00; 8:45 am]

BILLING CODE 4410-09-M

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated December 16, 1999, and published in the **Federal Register** on December 28, 1999 (64 FR 248), Knoll Pharmaceuticals, 30 North Jefferson Road, Whippany, New Jersey 07981, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Dihydromorphine (9145) .....	I
Hydromorphone (9150) .....	II

The firm plans to produce bulk product and finished dosage units for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Knoll Pharmaceuticals to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Knoll Pharmaceuticals on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: March 23, 2000.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 00-7873 Filed 3-29-00; 8:45 am]

BILLING CODE 4410-09-M

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on January 12, 2000, Lilly Del Caribe, Inc., Chemical Plant, Kilometer 146.7, State Road 2, Mayaguez, Puerto Rico 00680, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of dextropropoxyphene (9273) a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture bulk product for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance